• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2025.20068

The relationship of vitamin D with cardiometabolic risk factors in non-alcoholic fatty liver disease

[Internal diseases]
Elena Otarievna Demurcheva; Pavel Koroy; Alexandr Yagoda;

The aim of the investigation was to study the relationship of serum vitamin D levels with cardiometabolic risk factors in 171 patients with non-alcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus. In NAFLD, cytolytic, mesenchymal inflammatory and cholestatic syndromes of liver pathology, as well as the characteristics of the unfavorable course of type 2 diabetes mellitus were associated with a decrease in the concentration of vitamin D in the blood. Cardiometabolic risk factors (obesity, dyslipidemia, arterial hypertension, and metabolic syndrome) had no effect on serum vitamin D levels in patients with NAFLD, except for its lower values in cases of decreased high-density lipoproteins.

Download

References:
1. Younossi Z. M., Golabi P., Paik J. M., Henry A., Van Dongen C. [et al.]. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-1447. https://doi.org/10.1097/HEP.0000000000000004
2. Lee S., Jin M. H., Yoon J.-H. The contribution of vitamin D insufficiency to the onset of steatotic liver disease among individuals with metabolic dysfunction. Sci. Rep. 2024;14:6714. https://doi.org/10.1038/s41598-024-57380-9
3. Ravaioli F., Pivetti A., Di Marco L., Chrysanthi C., Frassanito G. [et al.]. Role of vitamin D in liver disease and complications of advanced chronic liver disease. Int. J. Mol. sci. 2022;23:9016. https://doi.org/10.3390/ijms23169016
4. Wang Y., Dan L., Fu T., Sun Y., Chen J. [et al.]. Serum 25-hydroxyvitamin D, type 2 diabetes, and liver-related outcomes: secondary data analysis of a prospective recruited cohort. Hepatol. Commun. 2023;7(11):e0291. https://doi.org/10.1097/HC9.0000000000000291
5. Cui A., Zhang T., Xiao P., Fan Z., Wang H. [et al.]. Global and regional prevalence of vitamin D deficiency in population-based studies from 2000 to 2022: a pooled analysis of 7.9 million participants. Front. Nutr. 2023;10:1070808. https://doi.org/10.3389/fnut.2023.1070808
6. Rihal V., Khan H., Kaur A., Singh T. G. Vitamin D as therapeutic modulator in cerebrovascular diseases: a mechanistic perspectives. Crit. Rev. Food Sci. Nutr. 2023;63(25):7772-7794. https://doi.org/10.1080/10408398.2022.2050349
7. Stepan M. D., Vintilescu S. B., Streată I., Podeanu M. A., Florescu D. N. The role of vitamin D in obese children with non-alcoholic fatty liver disease and associated metabolic syndrome. Nutrients. 2023;15(9):2113. https://doi.org/10.3390/nu15092113
8. Marziou A., Philouze C., Couturier C., Astier J., Obert P. [et al.]. Vitamin D supplementation improves adipose tissue inflammation and reduces hepatic steatosis in obese C57BL/6J mice. Nutrients. 2020;12(2):342. https://doi.org/10.3390/nu1202034
9. Znakharenko E. A., Gerasimenko O. N., Maksimov V. N. Clinical and molecular characteristics and peculiarities of nutritional status in non-alcoholic fatty liver disease. Therapy. 2025;11(5):26-35. (In Russ.). https://doi.org/10.18565/therapy.2025.5.26-35
10. Huang N., Su X., Yu T., Wu X., Lu B. [et al.]. Serum 25-hydroxy vitamin D level is associated with elastogra phy-detected liver fibrosis in patients with type 2 diabetes mellitus in China. Front. Endocrinol. 2024;15:1420088. https://doi.org/10.3389/fendo.2024.1420088
11. Yagoda A. V., Koroy P. V., Demurcheva E. O., Hvatalin N. E., Svetogurova A. D. [et al.]. Vitamin D as a marker of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Medical News of North Caucasus. 2023;18(2):131-135. https://doi.org/10.14300/mnnc.2023.18028
12. Yu H., Su X., Tao W., Sun W., Zhang X. [et al.]. Prevalence and characteristics of liver steatosis and fibrosis in type 2 diabetes mellitus (T2DM) patients: a cross-sectional study in populations of eastern China. BMJ Open. 2024;14:e087550. https://doi.org/10.1136/bmjopen-2024-087550
13. Zhao X., Sun J., Xin S., Xu X., Zhang X. Correlation between serum 25 (OH) D levels with insulin resistance and metabolic associated fatty liver disease – a retrospective study based on hinese patients with newly diagnosed type 2 diabetes mellitus. Curr. Diabetes Rev. 2025;21(7):56-66. https://doi.org/10.2174/0115733998297640240611065605
14. Kim Y., Chang Y., Ryu S., Cho I. Y., Kwon M.-J. [et al.]. Resolution of, and risk of incident nonalcoholic fatty liver disease with changes in serum 25-hydroxyvitamin D status. J. Clin. Endocrinol. Metabol. 2022;107(8):e3437-e3447. https://doi.org/10.1210/clinem/dgac255
15. Ciardullo S., Muraca E., Cannistraci R., Perra S., Lattuada G. [et al.]. Low 25 (OH) vitamin D levels are associated with increased prevalence of nonalcoholic fatty liver disease and significant liver fibrosis. Diabetes Metab. Res. Rev. 2023;39(5):e3628. https://doi.org/10.1002/dmrr.3628
16. Ji Y., Wei C.-B., Gu W., Hou L.-L. Relevance of vitamin D on NAFLD and liver fibrosis detected by vibration controlled transient elastography in US adults: a cross-sectional analysis of NHANES 2017-2018. Ann. Med. 2023;55(1):2209335. https://doi.org/10.1080/07853890.2023.2209335
17. Barchetta I., Cimini F. A., Cavallo M. G. Vitamin D and metabolic dysfunction-associated fatty liver disease (MAFLD): an update. Nutrients. 2020;12:3302. https://doi.org/10.3390/nu12113302
18. Ionica M., Aburel O. M., Vaduva A., Petrus A., Rațiu S. [et al.]. Vitamin D alleviates oxidative stress in adipose tissue and mesenteric vessels from obese patients with subclinical inflammation. Can. J. Physiol. Pharmacol. 2020;98:85-92. https://doi.org/10.1139/cjpp-2019-0340
19. Liu Y., Wang M., Xu W., Zhang H., Qian W. [et al.]. Active vitamin D supplementation alleviates initiation and progression of nonalcoholic fatty liver disease by repressing the p53 pathway. Life Sci. 2020;241:117086. https://doi.org/10.1016/j.lfs.2019.117086
20. Izadi A., Aliasghari F., Gargari B. P., Ebrahimi S. Strong association between serum vitamin D and vaspin levels, AIP, VAI and liver enzymes in NAFLD patients. Int. J. Vitam. Nutr. Res. 2020;90:59-66. https://doi.org/10.1024/0300-9831/a000443
21. Kumar M., Parchani A., Kant R., Das A. Relationship between vitamin D deficiency and non-alcoholic fatty liver disease: a cross-sectional study from a tertiary care center in Northern India. Cureus. 2023;15(2):e34921. https://doi.org/10.7759/cureus.34921
22. Ebrahimpour-Koujan S., Sohrabpour A. A., Giovannucci E., Vatannejad A., Esmaillzadeh A. Effects of vitamin D supplementation on liver fibrogenic factors, vitamin D receptor and liver fibrogenic microRNAs in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: an exploratory randomized clinical trial. Nutrition J. 2024;23:24. https://doi.org/10.1186/s12937-024-00911-x
23. Park D., Kwon H., Oh S.-W., Joh H. K., Hwang S. S. [et al.]. Is vitamin D an independent risk factor of nonalcoholic fatty liver disease?: a cross-sectional study of the healthy population. J. Korean Med. Sci. 2017;32:95-101. https://doi.org/10.3346/jkms.2017.32.1.95
24. Wan B., Gao Y., Zheng Y., Chen R. Association between serum 25-hydroxy vitamin D level and metabolic associated fatty liver disease (MAFLD) – a population-based study. Endocrine J. 2021;68(6):631-637.
25. Xing Y., Cheng T., Zhou F., Ma H. The association between vitamin D and type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease: an observational cross-sectional study. Diabetes Metab. Syndr. Obes. 2022;15:269-280. https://doi.org/10.2147/DMSO.S348870
26. Adolph T. E., Grander C., Grabherr F., Tilg H. Adipokines and non-alcoholic fatty liver disease: multiple interactions. Int. J. Mol. Sci. 2017;18:E1649. https://doi.org/10.3390/ijms18081649
27. Pop T. L., Sîrbe C., Benta G., Mititelu A., Grama A. The role of vitamin D and vitamin D binding protein in chronic liver diseases. Int. J. Mol. Sci. 2022;23:10705. https://doi.org/10.3390/ijms231810705
28. Taderegew M. M., Woldeamanuel G. G., Wondie A., Getawey A., Abegaz A. N. [et al.]. Vitamin D deficiency and its associated factors among patients with type 2 diabetes mellitus: a systematic review and meta-analysis. BMJ Open. 2023;13:e075607. https://doi.org/10.1136/bmjopen-2023-075607
29. Chen X., Wan Z., Geng T., Zhu K., Li R. [et al.]. Vitamin D status, vitamin D receptor polymorphisms, and risk of microvascular complications among individuals with type 2 diabetes: a prospective study. Diabetes. Care. 2023;46(2):270-277. https://doi.org/10.2337/dc22-0513
30. Cai J., Zhang Z., Liu J., Xiao X., Wang C. [et al.]. Correlation between serum 25-OH vitamin D expression and non-alcoholic fatty liver disease. Exp. Ther. Med. 2020;19(3):1681-1686. https://doi.org/10.3892/etm.2020.8411
31. Wang M., Wang M., Zhang R., Shen C., Zhang L. [et al.]. Influences of vitamin D levels and vitamin D-binding protein polymorphisms on nonalcoholic fatty liver disease risk in a Chinese Population. Ann. Nutr. Metab. 2022;78:61-72. https://doi.org/10.1159/000522193
32. Taban L., Stoian D., Timar B., Amzar D., Adela C. [et al.]. Vitamin D status and steatohepatitis in obese diabetic and non-diabetic patients. J. Clin. Med. 2022;11:5482. https://doi.org/10.3390/jcm11185482
33. Bouillon R., Schuit F., Antonio L., Rastinejad F. Vitamin D binding protein: a historic overview. Front. Endocrinol. 2020;10:910. https://doi.org/10.3389/fendo.2019.00910

Keywords: non-alcoholic fatty liver disease, vitamin D, cardiometabolic risk factors